November 15, 2026 — In the rapidly evolving landscape of modern medicine, the dialogues occurring within clinical halls, research symposia, and administrative boardrooms often provide a more accurate barometer of the state of healthcare than any single clinical trial. This week, MedPage Today compiles a series of critical observations from industry leaders and clinicians, highlighting the tensions between policy, patient care, and the ongoing struggle to maintain scientific integrity in an increasingly polarized climate.
From the complexities of chronic pain management to the systemic challenges facing major medical organizations, the following insights offer a window into the pressing concerns of the medical community.
1. The Paradox of Pain Management: Opioids and Sickle Cell Disease
The medical community continues to grapple with the fallout of the opioid crisis, yet for patients suffering from sickle cell disease, the pendulum may have swung too far toward restriction.
Main Facts:
Jeffrey Glassberg, MD, of the Icahn School of Medicine at Mount Sinai, recently underscored a fundamental clinical truth that has been obscured by regulatory fear: "Opioids cause pain. Full stop."
Implications:
Dr. Glassberg’s assertion points to the physiological reality of opioid-induced hyperalgesia, where chronic opioid use can paradoxicaly increase a patient’s sensitivity to pain. In the context of sickle cell disease—a condition characterized by excruciating vaso-occlusive crises—the management of pain remains a delicate tightrope. When the very medication used to treat the condition exacerbates the symptoms, clinicians are forced to re-evaluate long-term reliance on traditional analgesics in favor of newer, non-opioid, or multimodal pain management strategies. The discourse suggests a paradigm shift: move away from viewing opioids as a long-term solution and toward a model that addresses the underlying inflammatory and cellular pathology of the disease itself.
2. Institutional Turmoil: The American Diabetes Association Boycott
The intersection of institutional governance and clinical ethics reached a boiling point this week with the resignation of Christian Kohler, the former vice president of publications at the American Diabetes Association (ADA).
Chronology and Context:
The ADA has been embroiled in an internal and external conflict that has led to a significant boycott by high-profile researchers and clinicians. At the heart of this dispute are concerns regarding transparency, industry influence, and the direction of the organization’s research agenda.
Official Response:
"This is not a frivolous exercise for the boycotters," Kohler stated upon his departure. His resignation signals a deep-seated frustration within the ranks of the organization. The boycott, which has been gaining momentum throughout the latter half of 2026, reflects a broader skepticism regarding whether major health advocacy groups are truly prioritizing patient outcomes or if their agendas are being compromised by external institutional pressures.
3. Transparency in Pharmaceutical Safety: The Rezdiffra Case
At the annual Liver Meeting, the atmosphere was thick with professional tension as the conversation turned toward metabolic dysfunction-associated steatohepatitis (MASH) and the drug resmetirom (Rezdiffra).
Supporting Data:
David Goldberg, MD, of the Miller School of Medicine at the University of Miami, brought the room to a standstill during his presentation. "We can’t ignore the elephant in the room," Goldberg remarked, referring to a whistleblower lawsuit that alleges safety concerns surrounding the clinical trial data for Rezdiffra.
Implications:
The pharmaceutical industry often faces scrutiny, but the emergence of whistleblower allegations regarding a flagship drug for a rapidly growing condition like MASH poses a significant threat to public trust. If the safety profile of a major therapeutic agent is called into question, it risks setting back progress in a field that has only recently seen significant clinical breakthroughs. The medical community is now tasked with balancing the urgent need for MASH treatments with a rigorous demand for data integrity.
4. The Complexity of "Brain Fog" and Sleep Disorders
In the field of sleep medicine, the challenge often lies in the subjective nature of patient complaints. Anne Marie Morse, DO, of Geisinger Medical Center, offered a poignant perspective on how clinicians should interpret patient narratives regarding "brain fog."
Clinical Approach:
"Treat the answer as its own symptom," Dr. Morse advised.
Supporting Analysis:
For patients suffering from sleep disorders, "brain fog" is frequently dismissed as a secondary symptom or a vague complaint. However, Dr. Morse argues that by treating the patient’s own description as a diagnostic marker, physicians can gain deeper insights into the neurological and cognitive toll of sleep deprivation. This approach encourages a more empathetic and observant clinical practice, moving beyond standard questionnaires and into a more nuanced understanding of the patient’s daily cognitive reality.
5. The Erosion of Scientific Authority and Public Health
Perhaps the most alarming trend identified this week is the decline of public faith in scientific institutions. Georges Benjamin, MD, CEO of the American Public Health Association, addressed a survey revealing that roughly one in four U.S. adults harbor deep-seated myths regarding autism risks.
The Crisis of Misinformation:
"Science is supposed to be apolitical," Dr. Benjamin noted. However, the reality of 2026 is that medical findings are frequently filtered through a partisan lens. When public health guidance is perceived as political, the resulting erosion of trust has tangible, life-threatening consequences, particularly in the realm of vaccination and developmental health.
Institutional Criticism:
The issue of institutional trust was further compounded by the release of an overdue report from a new HHS vaccine task force. Elizabeth Jacobs, PhD, a founding member of Defend Public Health, was scathing in her assessment: "It will be more textual squid ink that accomplishes nothing other than reinforcing unfounded doubts about vaccines that have been cultivated by the HHS secretary for decades."
Her critique suggests that the problem is not merely a lack of public understanding, but a failure of leadership at the highest levels of government to provide clear, unbiased, and timely communication.
6. Shifting Standards: Prostate Cancer Screening
Amidst the turbulence of public health debates, there remains progress in clinical guideline development. Mark Ashamalla, MD, of Episcopal Health Services, highlighted a welcome clarity in the latest updates to prostate cancer screening guidelines.
Main Facts:
The American Cancer Society (ACS) has adopted a much more definitive stance on screening protocols. "Now [the American Cancer Society is] taking a much clearer position," Dr. Ashamalla noted. This move is expected to reduce the confusion that has plagued primary care physicians for years, providing a more standardized roadmap for early detection and intervention in prostate cancer cases.
7. Global Trends: The Gabapentinoid Surge
Finally, international data provides a glimmer of hope regarding the misuse of prescription medications. Rose Cairns, PhD, of the University of Sydney, commented on the trends surrounding the use of pregabalin in Australia.
Supporting Data:
After a sustained period of high utilization, the "gabapentinoid surge" is finally showing signs of reversal. "We think use of pregabalin is still far too high," Dr. Cairns noted, highlighting that while the trend is moving in the right direction, there is still significant work to be done in educating clinicians about the risks of over-prescribing gabapentinoids for off-label pain management.
Conclusion: The Path Forward
The voices heard this week across the medical landscape share a common theme: the need for rigor, transparency, and empathy. Whether it is the demand for honest data in pharmaceutical development, the struggle to de-politicize public health, or the nuanced care required for chronic pain patients, the medical profession is clearly in a state of self-reflection.
As we look toward the remainder of 2026, the challenge for practitioners and administrators alike will be to navigate these complexities without losing sight of the fundamental mission of medicine: to provide evidence-based, compassionate care in an increasingly complicated world. The insights from these experts serve as a reminder that science is not a static body of knowledge, but a dynamic, human-led endeavor that requires constant vigilance and an unwavering commitment to the truth.
